Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...
Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...
Anfield Index3d
Dave Davis: “Fans Beaten Down to Expect No Purchases Unless Players Sold”
Fans Beaten Down to Expect No Purchases Unless Players Sold” written on March 14, 2025 by Jackson Lee. This article is about ...
Nature5y
Anabolic steroid abuse can lead to focal segmental glomerulosclerosis
Long-term abuse of anabolic steroids can lead to focal segmental glomerulosclerosis (FSGS), according to a recent study. Although anabolic steroid abuse is known to have adverse effects on the ...
Hosted on MSN1mon
Travere therapeutics SVP Elizabeth Reed sells $188,240 in stock
The company aims to complete the sNDA submission by the first quarter of 2025, which could potentially lead to Filspari entering the FSGS market by late 2025. In addition, Canaccord Genuity ...
TEAMtalk on MSN4d
Liverpool escalate plans to sign sublime Prem leader as FSG’s three key transfer criteria is revealed
TEAMtalk can reveal Liverpool are stepping up their interest in Dean Huijsen, with the Bournemouth star satisfying three key ...
Sports Illustrated26d
Chicago Cubs Bring Fans Together for Life-Saving Surgery and Life-Long Friendship
Her diagnosis of focal segmental glomerulosclerosis (FSGS) would eventually result in kidney failure. Her caregivers laid out a 10-year lifespan if no action were to be taken. Vasquez would soon ...
Travere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGS
Travere Therapeutics (TVTX) has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking priority review ...